SlideShare a Scribd company logo
Pitfalls of
PGTa
Dr Kaberi Banerjee
WHAT IS PGS WHAT IS PGTA PROBLEMS
WITH PGTA
VARIOUS
STUDIES
The Earlier
names of
Genetic Tests
on Embryos
Current names of Genetic Tests on the
Embryo
PGTa claims to reduce
implantation failure in IVF and
reduce the risk of miscarriages.
It is a very expensive test!
Is it true?
Some Facts of
PGTa
• All cells in any embryo doesn’t
demonstrate aneuploidies i.e
chromosomal abnormalities.
There are only small number of
cells which shows abnormalities.
If embryo biopsy shows abnormal
DNA, it is not the whole cell will
be abnormal.
Some Facts of
PGTa
• It is also observed that abnormal cells
often self-destruct and some cells self-
correct by themselves. This self-correction
happens more in cells which makes baby
than the cells which makes placenta
(trophectoderm). For PGT-a, embryo
biopsy is taken from trophectoderm. This
shows that there is no benefit of doing
blastocyst stage embryo biopsy as cells
which are tested are of outer layer not the
inner layer which forms the baby.
The STAR Study
• A total of 661 women (average age 33.7 ± 3.6
years) were randomized to PGT-A (n = 330) or
morphology alone (n = 331).
• PGT-A did not improve overall pregnancy
outcomes in all women, as analyzed per embryo
transfer or per ITT. There was a significant
increase in OPR per embryo transfer with the
use of PGT-A in the subgroup of women aged
35-40 years who had two or more embryos that
could be biopsied, but this was not significant
when analyzed by ITT.
SHORT COMMUNICATION Open Access
Preimplantation genetic screening- the
required RCT that has not yet been carried
out
Raoul Orvieto1,2
Abstract
The utilization of trophectoderm biopsy combined with comprehensive chromosome screening (CCS) tests for
embryonic aneuploidy was recently suggested to improve IVF outcome, however, not without criticisms. The
ongoing discussion on the unrestricted clinical adoption of preimplantation genetic screening (PGS) has called for a
proper randomized controlled trial (RCT), aiming to further evaluate the cumulative live birth rates (LBRs) following
Orvieto Reproductive Biology and Endocrinology (2016) 14:35
DOI 10.1186/s12958-016-0171-z
• The utilization of trophectoderm biopsy combined
with comprehensive chromosome screening (CCS) tests
for embryonic aneuploidy was recently suggested to
improve IVF outcome, however, not without criticisms.
The ongoing discussion on the unrestricted clinical
adoption of preimplantation genetic screening (PGS) has
called for a proper randomized controlled trial (RCT),
aiming to further evaluate the cumulative live birth rates
(LBRs) following a single oocyte retrieval, utilizing all
fresh and frozen embryos. Since this study seems not to
appear for various reasons, we present herewith, the
hypothetical required RCT based on the hitherto
published literature.
• After implementing data from the hitherto published
literature on blastulation and aneuploidy rates, the rate
of mosaicism and technical errors and implantation
rates/LBRs of non-PGS day-3 and blastocyst and PGS
blastocyst, we could clearly demonstrate the superiority
of non-PGS embryo (day-3 and blastocyst) transfer over
PGS blastocyst transfer, in terms of cumulative LBR
(18.2–50 % vs 7.6–12.6 %, respectively).
• We therefore believe that until the proper, non-
hypothetical RCT on the efficacy of this procedure will
appear, PGS should be offered only under study
conditions, and with appropriate informed consents.
Overall same , but can show as 50% and 100%
Depends which data you want to show!
Non PGS-50%?
10
8
6
4
2+2
-ve/+ve
PGS-100%?
10
8
6
4
2
+ve
Extra Cost
Freezing
Transfer Time
Extra Cost
PGS
Personnel
Laboratory
WaitingTime
Assumptions
• Blastulation Rate- 47%
• Aneuploidy Rate- 59%
• IR-D3 21-50%, Non PGS D5
38-47%, PGS D5 39-65%
• Mosaicism and Technical
Errors reduce LBR
SHORT COMMUNICATION Open Access
Preimplantation genetic screening- the
required RCT that has not yet been carried
out
Raoul Orvieto1,2
Abstract
The utilization of trophectoderm biopsy combined with comprehensive chromosome screening (CCS) tests for
embryonic aneuploidy was recently suggested to improve IVF outcome, however, not without criticisms. The
ongoing discussion on the unrestricted clinical adoption of preimplantation genetic screening (PGS) has called for a
proper randomized controlled trial (RCT), aiming to further evaluate the cumulative live birth rates (LBRs) following
a single oocyte retrieval, utilizing all fresh and frozen embryos. Since this study seems not to appear for various
reasons, we present herewith, the hypothetical required RCT based on the hitherto published literature.
After implementing data from the hitherto published literature on blastulation and aneuploidy rates, the rate of
mosaicism and technical errors and implantation rates/LBRs of non-PGS day-3 and blastocyst and PGS blastocyst,
we could clearly demonstrate the superiority of non-PGS embryo (day-3 and blastocyst) transfer over PGS blastocyst
transfer, in terms of cumulative LBR (18.2–50 % vs 7.6–12.6 %, respectively).
Orvieto Reproductive Biology and Endocrinology (2016) 14:35
DOI 10.1186/s12958-016-0171-z
For the propose of the analysis, we will assume that
each group yielded 100 day-3 embryos and that all
In a recent study [12] evaluating the accuracy of troph-
ectoderm multiple biopsies using next-generation
Fig. 1 The required hypothetical RCT
• Presented reanalysis here of the recently
published STAR study [8], which already has
been affecting IVF practice worldwide,
reveals significant shortcomings in the study’s
statistical analyses. Those, however, do not
change the principal conclusion of the STAR
study that PGT-A does not favorably affect IVF
outcomes by increasing pregnancy chances or
reducing miscarriage risks.
• The STAR study thus reveals that PGT-A
does not beneficially affect IVF outcomes in
confirmation of another relatively recent
study in women 37 years and older by Kang
et al. Like the STAR study, Kang et al. reported
seemingly improved live birth rates following
PGT-A but this outcome advantage, actually,
reversed itself after correct intent-to-treat
analysis of outcomes with reference cycle
start: Pregnancy as well as live birth rates,
indeed, ended up to be significantly higher in
control non-PGT-A patients (49.5 vs 21.5%
and 39.8 vs 19.9%).
• Considering all presented evidence here, it
is difficult to understand what further
argument can be made for the continuous
routine clinical utilization of PGT-A to improve
IVF outcomes.
•
COMMENTARY
Preimplantation genetic testing for aneuploidy (PGT-A)
—finally revealed
Raoul Orvieto1,2
& Norbert Gleicher3,4,5,6
Received: 10 December 2019 /Accepted: 27 January 2020 /Published online: 2 February 2020
# Springer Science+Business Media, LLC, part of Springer Nature 2020
Keywords PGT-A . PGS . Live-birth rate . Intention to treat . RCT
Introduction
Natural fecundity of women decreases gradually and more
rapidly after age 37 years. This decrease is accompanied by
aneuploidies. The procedure was, ther
formed biopsying 1–2 blastomeres of d
embryos, often given the acronym PGS
This form of embryo testing has, sinc
Journal of Assisted Reproduction and Genetics (2020) 37:669–672
https://doi.org/10.1007/s10815-020-01705-w
4/5/2021 Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation - Cornelisse, S - 2020 | Cochrane Library
Authors' conclusions
There is insu icient good‐quality evidence of a di erence in cumulative live birth rate, live birth rate a er the first embryo transfer, or miscarriage rate
between IVF with and IVF without PGT‐A as currently performed. No data were available on ongoing pregnancy rates. The e ect of PGT‐A on clinical
pregnancy rate is uncertain.
Women need to be aware that it is uncertain whether PGT‐A with the use of genome‐wide analyses is an e ective addition to IVF, especially in view of the
invasiveness and costs involved in PGT‐A. PGT‐A using FISH for the genetic analysis is probably harmful.
The currently available evidence is insu icient to support PGT‐A in routine clinical practice.
Plain language summary
Available in English Español ‫ر‬ Français 한국어 Bahasa Malaysia
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005291.pub3/full 1/6
Cochrane Database of Systematic Reviews Review - Intervention New search
Abstract
Available in English Español ‫ر‬ Français 한국어
Background
In in vitro fertilisation (IVF) with or without intracytoplasmic sperm injection (ICSI), selection of the most competent embryo(s) for transfer is based on
morphological criteria. However, many women do not achieve a pregnancy even a er 'good quality' embryo transfer. One of the presumed causes is that
such morphologically normal embryos have an abnormal number of chromosomes (aneuploidies). Preimplantation genetic testing for aneuploidies (PGT‐
Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro
fertilisation
,
Simone Cornelisse ,
Miriam Zagers ,
Elena Kostova ,
Kathrin Fleischer ,
Madelon Wely Sebastiaan Mastenbroek Authors' declarations of interest
Version published: 08 September 2020 Version history
https://doi.org/10.1002/14651858.CD005291.pub3
Preimplantation genetic
screening: what is the
clinical efficiency?
In the current practice of in vitro fertilization (IVF), preim-
plantation genetic screening (PGS) is increasingly used to
select embryos for transfer. This strategy is designed to maxi-
mize the probability of embryo implantation by eliminating
embryos with low implantation potential from the cohort.
However, PGS is inherently imperfect. Errors may occur dur-
ing the genetic analysis of the small amount of DNA collected.
More importantly, mitotic mosaicism, whose precise inci-
dence in the preimplantation embryo is not known, may
lead to sampling errors due to the intentionally limited collec-
tion of cells in the trophectoderm biopsy. In this manner,
abnormal cells may be collected in an otherwise euploid em-
bryo and vice versa. Therefore, it is inevitable that some
normal embryos will be discarded, leading to an overall
EI(idealized). The efficiency of the screening process can then
be expressed as:
Efficiency ¼
EIðscreenedÞ
EIðidealizedÞ
The percentage of embryos lost in the process can then be
calculated as:
% embryos lost ¼ 1 $ Efficiency
The depiction of this analysis is most easily demonstrated
in a graphic fashion. For this example, let us consider a hypo-
thetical cohort of embryos from ‘‘good-prognosis’’ patients
(2), under the age of 35 years, with multiple blastocysts in
the 4AA or 4BB category, an unscreened implantation rate
of 50%, and an ‘‘aneuploidy’’ rate of 40%. In the parlance
of this calculation:
EIðunscreenedÞ ¼ 0:50
INKLINGS
• Errors may occur during the genetic analysis of the small
amount of DNA collected.
• Mitotic mosaicism may lead to sampling errors
• Some normal embryos will be discarded, leading to an
overall decrease in the cumulative pregnancy rate
achievable by the eventual transfer of all embryos in the
cohort.
• Real possibility of damage to the blastocyst as result of the
trophectoderm biopsy.
• No studies have addressed the impact of trophectoderm
biopsy in embryos with less than ideal morphologic
characteristics, in older patients, or after an intervening
cryopreservation procedure.
Preimplantation genetic
screening: what is the
clinical efficiency?
In the current practice of in vitro fertilization (IVF), preim-
plantation genetic screening (PGS) is increasingly used to
select embryos for transfer. This strategy is designed to maxi-
mize the probability of embryo implantation by eliminating
embryos with low implantation potential from the cohort.
However, PGS is inherently imperfect. Errors may occur dur-
ing the genetic analysis of the small amount of DNA collected.
EI(idealized). The efficiency of the
be expressed as:
Efficiency ¼
EIðscreenedÞ
EIðidealizedÞ
The percentage of embryos lo
calculated as:
% embryos lost ¼ 1 $ Efficienc
The depiction of this analysis
in a graphic fashion. For this exam
INKLINGS
Clinical application of PGT‐A: is the price too high?
T El‐Toukhy
Guys and St. Thomas Hospital NHS Trust, London, UK
Linked article: This is a mini commentary on K Neumann et al., pp. 710–718 in this issue. To view this article visit
https://doi.org/10.1111/1471-0528.16089
Published Online 8 March 2020.
Pre‐implantation genetic testing for
aneuploidy (PGT‐A) continues to pro-
voke interest, discussion and debate in
the field of reproductive medicine.
The two touted benefits of compre-
hensive screening of pre‐implantation
embryos for chromosomal aneuploidies
in in vitro fertilisation (IVF) treat-
ment are improvement in the live
birth rate per cycle and reduction in
miscarriage risk.
Two recent large randomised trials
employing two different techniques
for PGT‐A (ESTEEM Trial – Verpoest
et al. Hum Reprod 2018;33:1767–76
et al., Reprod Biomed Online 2019;
39:617–23).
In this issue of our journal, the
study of Neumann et al. (BJOG
2020;127:710–8) focused on the
cost‐effectiveness of PGT‐A, using
data from the ESTEEM trial. The
study demonstrated the high cost
of preventing one miscarriage
through the application of PGT‐A,
in both high‐cost and low‐cost
healthcare settings. This result is con-
sistent with the conclusion of a ‘theo-
retical’ cost‐effectiveness study in a UK
setting (Scriven, Reprod Biol Endocrinol
cycles to achieve a live birth, it
would seem more reasonable to use
the limited resources for funding
more standard IVF cycles to achieve
more live births rather than chasing
the possibility of fewer miscarriages
and end up with fewer babies.
Although the initial PGT‐A results
involving day‐3 embryo biopsy and
fluorescence in situ hybridisation
were disappointing, it was expected
that improvement in blastocyst cul-
ture, embryo cryopreservation and
molecular genetic testing technolo-
gies would enable PGT‐A to achieve
Economic analysis of preimplantation genetic testing for aneuploidy
Pre‐implantation genetic testing for
aneuploidy (PGT‐A) continues to pro-
voke interest, discussion and debate in
the field of reproductive medicine.
The two touted benefits of compre-
hensive screening of pre‐implantation
embryos for chromosomal aneuploidies
in in vitro fertilisation (IVF) treat-
ment are improvement in the live
birth rate per cycle and reduction in
miscarriage risk.
Two recent large randomised trials
employing two different techniques
for PGT‐A (ESTEEM Trial – Verpoest
et al. Hum Reprod 2018;33:1767–76
and STAR Study – Munne et al. Fertil
Steril 2019;112:1071–9) have shown
no improvement in the live birth rate
per IVF cycle started in screened
cycles compared with no screening.
The ESTEEM trial did not show a
shorter time to pregnancy and the
STAR study did not show a reduc-
tion in the miscarriage rate associated
et al., Reprod Biomed Online 2019;
39:617–23).
In this issue of our journal, the
study of Neumann et al. (BJOG
2020;127:710–8) focused on the
cost‐effectiveness of PGT‐A, using
data from the ESTEEM trial. The
study demonstrated the high cost
of preventing one miscarriage
through the application of PGT‐A,
in both high‐cost and low‐cost
healthcare settings. This result is con-
sistent with the conclusion of a ‘theo-
retical’ cost‐effectiveness study in a UK
setting (Scriven, Reprod Biol Endocrinol
2017;15:49). Both studies highlighted
the financial burden of PGT‐A and
emphasised that applying PGT‐A to all
IVF cycles in women below the age of
40 years would be a very expensive
approach to reduce the risk of
miscarriage.
Although it is important not to
underestimate the emotional and
cycles to ach
would seem m
the limited r
more standard
more live birt
the possibility
and end up wi
Although th
involving day‐
fluorescence
were disappoi
that improvem
ture, embryo
molecular gen
gies would en
its potential
IVF outcome
Reprod 2014;2
recent publica
those improved
the study of N
2020;127:710–8
reminder of th
ased objective
• Any Intervention that claims to
increase the pregnancy rate in IVF
must stand the test of time…till
then must be clearly offered as an
experimental test and at least
should not financially drain the
patient.

More Related Content

What's hot

Endometriosis in IVF
Endometriosis in IVFEndometriosis in IVF
Endometriosis in IVF
Sujoy Dasgupta
 
Pgd an overview_dr.laila_bastaki
Pgd an overview_dr.laila_bastakiPgd an overview_dr.laila_bastaki
Pgd an overview_dr.laila_bastaki
鋒博 蔡
 
Novel treatments to trigger final follicular maturation and luteal phase support
Novel treatments to trigger final follicular maturation and luteal phase supportNovel treatments to trigger final follicular maturation and luteal phase support
Novel treatments to trigger final follicular maturation and luteal phase support
Sandro Esteves
 
Endometrial recptivity
Endometrial recptivityEndometrial recptivity
Endometrial recptivity
Aboubakr Elnashar
 
PGD and PGS in India - the good, bad and ugly
PGD and PGS in India - the good, bad and uglyPGD and PGS in India - the good, bad and ugly
PGD and PGS in India - the good, bad and ugly
Dr Aniruddha Malpani
 
Ovarian Stimulation Protocols
Ovarian Stimulation ProtocolsOvarian Stimulation Protocols
Ovarian Stimulation Protocols
Hesham Gaber
 
EMPTY FOLLICLE SYNDROME
EMPTY FOLLICLE SYNDROMEEMPTY FOLLICLE SYNDROME
EMPTY FOLLICLE SYNDROME
Aboubakr Elnashar
 
Gn rh agonist trigger in gnrh antagonist cycles
Gn rh agonist trigger in gnrh antagonist cyclesGn rh agonist trigger in gnrh antagonist cycles
Gn rh agonist trigger in gnrh antagonist cycles
IVF-Mohamed Youssef AF
 
In vitro fertilization and embryo transfer "IVF"; Overview on the Story FRO...
In vitro fertilization and embryo transfer "IVF"; Overview on the Story FRO...In vitro fertilization and embryo transfer "IVF"; Overview on the Story FRO...
In vitro fertilization and embryo transfer "IVF"; Overview on the Story FRO...
Ahmed Mowafy
 
Controlled Ovarian Hyperstimulation in PCOS women
Controlled Ovarian Hyperstimulation in PCOS womenControlled Ovarian Hyperstimulation in PCOS women
Controlled Ovarian Hyperstimulation in PCOS women
Osama Abdalmageed
 
Number of oocytes and progesterone levels in IVF: Do they matter?
Number of oocytes and progesterone levels in IVF: Do they matter?Number of oocytes and progesterone levels in IVF: Do they matter?
Number of oocytes and progesterone levels in IVF: Do they matter?
Sandro Esteves
 
Panel IUI by DR SHASHWAT JANI ( Optimizing Success in Intrauterine Inseminati...
Panel IUI by DR SHASHWAT JANI ( Optimizing Success in Intrauterine Inseminati...Panel IUI by DR SHASHWAT JANI ( Optimizing Success in Intrauterine Inseminati...
Panel IUI by DR SHASHWAT JANI ( Optimizing Success in Intrauterine Inseminati...
DR SHASHWAT JANI
 
PERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHAR
PERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHARPERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHAR
PERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHAR
Aboubakr Elnashar
 
Setting up of art lab by Dr. Renukadevi
Setting up of art lab by Dr. RenukadeviSetting up of art lab by Dr. Renukadevi
Setting up of art lab by Dr. Renukadevi
Morris Jawahar
 
Sperm DNA Fragmentation in Male Infertility
Sperm DNA Fragmentation in Male InfertilitySperm DNA Fragmentation in Male Infertility
Sperm DNA Fragmentation in Male Infertility
Sandro Esteves
 
IMSI
IMSIIMSI
Day3 versus Day5 Embryo Transfer
Day3 versus Day5 Embryo TransferDay3 versus Day5 Embryo Transfer
Day3 versus Day5 Embryo Transfer
Sujoy Dasgupta
 
Fertility preservation 3
Fertility preservation 3Fertility preservation 3
Fertility preservation 3
Basalama Ali
 
Blastocyst Culture Benefit and Harms
Blastocyst Culture  Benefit and HarmsBlastocyst Culture  Benefit and Harms
Blastocyst Culture Benefit and Harms
Dr. Jyoti Malik
 
Ovarian Stimulation in IUI- Overview Sr. Jyoti Bhaskar
Ovarian Stimulation in IUI- Overview Sr. Jyoti BhaskarOvarian Stimulation in IUI- Overview Sr. Jyoti Bhaskar
Ovarian Stimulation in IUI- Overview Sr. Jyoti Bhaskar
Lifecare Centre
 

What's hot (20)

Endometriosis in IVF
Endometriosis in IVFEndometriosis in IVF
Endometriosis in IVF
 
Pgd an overview_dr.laila_bastaki
Pgd an overview_dr.laila_bastakiPgd an overview_dr.laila_bastaki
Pgd an overview_dr.laila_bastaki
 
Novel treatments to trigger final follicular maturation and luteal phase support
Novel treatments to trigger final follicular maturation and luteal phase supportNovel treatments to trigger final follicular maturation and luteal phase support
Novel treatments to trigger final follicular maturation and luteal phase support
 
Endometrial recptivity
Endometrial recptivityEndometrial recptivity
Endometrial recptivity
 
PGD and PGS in India - the good, bad and ugly
PGD and PGS in India - the good, bad and uglyPGD and PGS in India - the good, bad and ugly
PGD and PGS in India - the good, bad and ugly
 
Ovarian Stimulation Protocols
Ovarian Stimulation ProtocolsOvarian Stimulation Protocols
Ovarian Stimulation Protocols
 
EMPTY FOLLICLE SYNDROME
EMPTY FOLLICLE SYNDROMEEMPTY FOLLICLE SYNDROME
EMPTY FOLLICLE SYNDROME
 
Gn rh agonist trigger in gnrh antagonist cycles
Gn rh agonist trigger in gnrh antagonist cyclesGn rh agonist trigger in gnrh antagonist cycles
Gn rh agonist trigger in gnrh antagonist cycles
 
In vitro fertilization and embryo transfer "IVF"; Overview on the Story FRO...
In vitro fertilization and embryo transfer "IVF"; Overview on the Story FRO...In vitro fertilization and embryo transfer "IVF"; Overview on the Story FRO...
In vitro fertilization and embryo transfer "IVF"; Overview on the Story FRO...
 
Controlled Ovarian Hyperstimulation in PCOS women
Controlled Ovarian Hyperstimulation in PCOS womenControlled Ovarian Hyperstimulation in PCOS women
Controlled Ovarian Hyperstimulation in PCOS women
 
Number of oocytes and progesterone levels in IVF: Do they matter?
Number of oocytes and progesterone levels in IVF: Do they matter?Number of oocytes and progesterone levels in IVF: Do they matter?
Number of oocytes and progesterone levels in IVF: Do they matter?
 
Panel IUI by DR SHASHWAT JANI ( Optimizing Success in Intrauterine Inseminati...
Panel IUI by DR SHASHWAT JANI ( Optimizing Success in Intrauterine Inseminati...Panel IUI by DR SHASHWAT JANI ( Optimizing Success in Intrauterine Inseminati...
Panel IUI by DR SHASHWAT JANI ( Optimizing Success in Intrauterine Inseminati...
 
PERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHAR
PERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHARPERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHAR
PERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHAR
 
Setting up of art lab by Dr. Renukadevi
Setting up of art lab by Dr. RenukadeviSetting up of art lab by Dr. Renukadevi
Setting up of art lab by Dr. Renukadevi
 
Sperm DNA Fragmentation in Male Infertility
Sperm DNA Fragmentation in Male InfertilitySperm DNA Fragmentation in Male Infertility
Sperm DNA Fragmentation in Male Infertility
 
IMSI
IMSIIMSI
IMSI
 
Day3 versus Day5 Embryo Transfer
Day3 versus Day5 Embryo TransferDay3 versus Day5 Embryo Transfer
Day3 versus Day5 Embryo Transfer
 
Fertility preservation 3
Fertility preservation 3Fertility preservation 3
Fertility preservation 3
 
Blastocyst Culture Benefit and Harms
Blastocyst Culture  Benefit and HarmsBlastocyst Culture  Benefit and Harms
Blastocyst Culture Benefit and Harms
 
Ovarian Stimulation in IUI- Overview Sr. Jyoti Bhaskar
Ovarian Stimulation in IUI- Overview Sr. Jyoti BhaskarOvarian Stimulation in IUI- Overview Sr. Jyoti Bhaskar
Ovarian Stimulation in IUI- Overview Sr. Jyoti Bhaskar
 

Similar to Pitfalls of PGTa

1 s2.0-s0929664613000958-main
1 s2.0-s0929664613000958-main1 s2.0-s0929664613000958-main
1 s2.0-s0929664613000958-main
鋒博 蔡
 
Mu (1)
Mu (1)Mu (1)
Mu (1)
鋒博 蔡
 
Mu (2)
Mu (2)Mu (2)
Mu (2)
鋒博 蔡
 
Mu
MuMu
Mu
MuMu
Mu
MuMu
Mu
MuMu
Preimplantation Genetic Testing - Dr Kaberi Banerjee
Preimplantation Genetic Testing - Dr Kaberi BanerjeePreimplantation Genetic Testing - Dr Kaberi Banerjee
Preimplantation Genetic Testing - Dr Kaberi Banerjee
Kaberi Banerjee
 
Cgh
CghCgh
Munne Array Cgh Update 2010 05
Munne Array Cgh Update 2010 05Munne Array Cgh Update 2010 05
Munne Array Cgh Update 2010 05
smunne
 
論文
論文論文
論文
t7260678
 
Recurrent spontaneous abortion
Recurrent spontaneous abortionRecurrent spontaneous abortion
Recurrent spontaneous abortion
mothersafe
 
Introduction: Preimplantation genetic screening is alive and very well. Meldr...
Introduction: Preimplantation genetic screening is alive and very well. Meldr...Introduction: Preimplantation genetic screening is alive and very well. Meldr...
Introduction: Preimplantation genetic screening is alive and very well. Meldr...
鋒博 蔡
 
1 s2.0-s0015028213027441-main
1 s2.0-s0015028213027441-main1 s2.0-s0015028213027441-main
1 s2.0-s0015028213027441-main
鋒博 蔡
 
Why Not Era
Why Not EraWhy Not Era
Why Not Era
Kaberi Banerjee
 
Preimplantation genetic screening (pgs) current ppt
Preimplantation genetic screening (pgs)  current     pptPreimplantation genetic screening (pgs)  current     ppt
Preimplantation genetic screening (pgs) current ppt
鋒博 蔡
 
35170
3517035170
35170
鋒博 蔡
 
35170
3517035170
35170
鋒博 蔡
 
35170
3517035170
35170
鋒博 蔡
 
Preimplantation genetic screening (pgs) current ppt
Preimplantation genetic screening (pgs)  current     pptPreimplantation genetic screening (pgs)  current     ppt
Preimplantation genetic screening (pgs) current ppt
鋒博 蔡
 

Similar to Pitfalls of PGTa (20)

1 s2.0-s0929664613000958-main
1 s2.0-s0929664613000958-main1 s2.0-s0929664613000958-main
1 s2.0-s0929664613000958-main
 
Mu (1)
Mu (1)Mu (1)
Mu (1)
 
Mu (2)
Mu (2)Mu (2)
Mu (2)
 
Mu
MuMu
Mu
 
Mu
MuMu
Mu
 
Mu
MuMu
Mu
 
Mu
MuMu
Mu
 
Preimplantation Genetic Testing - Dr Kaberi Banerjee
Preimplantation Genetic Testing - Dr Kaberi BanerjeePreimplantation Genetic Testing - Dr Kaberi Banerjee
Preimplantation Genetic Testing - Dr Kaberi Banerjee
 
Cgh
CghCgh
Cgh
 
Munne Array Cgh Update 2010 05
Munne Array Cgh Update 2010 05Munne Array Cgh Update 2010 05
Munne Array Cgh Update 2010 05
 
論文
論文論文
論文
 
Recurrent spontaneous abortion
Recurrent spontaneous abortionRecurrent spontaneous abortion
Recurrent spontaneous abortion
 
Introduction: Preimplantation genetic screening is alive and very well. Meldr...
Introduction: Preimplantation genetic screening is alive and very well. Meldr...Introduction: Preimplantation genetic screening is alive and very well. Meldr...
Introduction: Preimplantation genetic screening is alive and very well. Meldr...
 
1 s2.0-s0015028213027441-main
1 s2.0-s0015028213027441-main1 s2.0-s0015028213027441-main
1 s2.0-s0015028213027441-main
 
Why Not Era
Why Not EraWhy Not Era
Why Not Era
 
Preimplantation genetic screening (pgs) current ppt
Preimplantation genetic screening (pgs)  current     pptPreimplantation genetic screening (pgs)  current     ppt
Preimplantation genetic screening (pgs) current ppt
 
35170
3517035170
35170
 
35170
3517035170
35170
 
35170
3517035170
35170
 
Preimplantation genetic screening (pgs) current ppt
Preimplantation genetic screening (pgs)  current     pptPreimplantation genetic screening (pgs)  current     ppt
Preimplantation genetic screening (pgs) current ppt
 

More from Kaberi Banerjee

Strategies for improving success in Poor responders
Strategies for improving success in Poor respondersStrategies for improving success in Poor responders
Strategies for improving success in Poor responders
Kaberi Banerjee
 
Embryo Transfer- Tips and Tricks to improve success
Embryo Transfer- Tips and Tricks to improve successEmbryo Transfer- Tips and Tricks to improve success
Embryo Transfer- Tips and Tricks to improve success
Kaberi Banerjee
 
The Thin endometrium- Where are we today?
The Thin endometrium- Where are we today?The Thin endometrium- Where are we today?
The Thin endometrium- Where are we today?
Kaberi Banerjee
 
Endometrial Receptivity Array- Dr Kaberi Banerjee
Endometrial Receptivity Array- Dr Kaberi BanerjeeEndometrial Receptivity Array- Dr Kaberi Banerjee
Endometrial Receptivity Array- Dr Kaberi Banerjee
Kaberi Banerjee
 
Single Embryo Trasnfer- Dr Kaberi Banerjee
Single Embryo Trasnfer- Dr Kaberi BanerjeeSingle Embryo Trasnfer- Dr Kaberi Banerjee
Single Embryo Trasnfer- Dr Kaberi Banerjee
Kaberi Banerjee
 
Chronic endometritis and its effect on Fertility
Chronic endometritis and its effect on FertilityChronic endometritis and its effect on Fertility
Chronic endometritis and its effect on Fertility
Kaberi Banerjee
 
Cleavage vs Blastocyst- Dr Kaberi Banerjee
Cleavage vs Blastocyst- Dr Kaberi BanerjeeCleavage vs Blastocyst- Dr Kaberi Banerjee
Cleavage vs Blastocyst- Dr Kaberi Banerjee
Kaberi Banerjee
 
Transforming Reproductive Medicine with AI
Transforming Reproductive Medicine with AITransforming Reproductive Medicine with AI
Transforming Reproductive Medicine with AI
Kaberi Banerjee
 
Elective Single Embryo Transfer- An Insight
Elective Single  Embryo Transfer- An InsightElective Single  Embryo Transfer- An Insight
Elective Single Embryo Transfer- An Insight
Kaberi Banerjee
 
CLEAVAGE OR BLASTOCYST EMBRYO TRANSFER
CLEAVAGE OR BLASTOCYST EMBRYO TRANSFERCLEAVAGE OR BLASTOCYST EMBRYO TRANSFER
CLEAVAGE OR BLASTOCYST EMBRYO TRANSFER
Kaberi Banerjee
 
Fallopian tube blockage
Fallopian tube blockageFallopian tube blockage
Fallopian tube blockage
Kaberi Banerjee
 
Evaluation of Quality of Life in Infertile Couples
Evaluation of Quality of Life in Infertile CouplesEvaluation of Quality of Life in Infertile Couples
Evaluation of Quality of Life in Infertile Couples
Kaberi Banerjee
 
Management of IVF Pregnancy
Management of IVF PregnancyManagement of IVF Pregnancy
Management of IVF Pregnancy
Kaberi Banerjee
 
Psychosocial & Ethical Dilemma Surrounding Fertility Preservation in Young Ca...
Psychosocial & Ethical Dilemma Surrounding Fertility Preservation in Young Ca...Psychosocial & Ethical Dilemma Surrounding Fertility Preservation in Young Ca...
Psychosocial & Ethical Dilemma Surrounding Fertility Preservation in Young Ca...
Kaberi Banerjee
 
Myoma in Infertility Dilemmas in Management
Myoma in Infertility Dilemmas in ManagementMyoma in Infertility Dilemmas in Management
Myoma in Infertility Dilemmas in Management
Kaberi Banerjee
 
Role of Hysteroscopy in Difficult Embryo Transfers
Role of Hysteroscopy in Difficult Embryo TransfersRole of Hysteroscopy in Difficult Embryo Transfers
Role of Hysteroscopy in Difficult Embryo Transfers
Kaberi Banerjee
 
Role of Subcutaneous G-CSF Infusion in Thin Endometrium
Role of Subcutaneous G-CSF Infusion in Thin EndometriumRole of Subcutaneous G-CSF Infusion in Thin Endometrium
Role of Subcutaneous G-CSF Infusion in Thin Endometrium
Kaberi Banerjee
 
Medically Complicated IVF Patient
Medically Complicated IVF PatientMedically Complicated IVF Patient
Medically Complicated IVF Patient
Kaberi Banerjee
 
Dilemmas in Management of Fibroid
Dilemmas in Management of FibroidDilemmas in Management of Fibroid
Dilemmas in Management of Fibroid
Kaberi Banerjee
 
Failed IVF Cycle
Failed IVF CycleFailed IVF Cycle
Failed IVF Cycle
Kaberi Banerjee
 

More from Kaberi Banerjee (20)

Strategies for improving success in Poor responders
Strategies for improving success in Poor respondersStrategies for improving success in Poor responders
Strategies for improving success in Poor responders
 
Embryo Transfer- Tips and Tricks to improve success
Embryo Transfer- Tips and Tricks to improve successEmbryo Transfer- Tips and Tricks to improve success
Embryo Transfer- Tips and Tricks to improve success
 
The Thin endometrium- Where are we today?
The Thin endometrium- Where are we today?The Thin endometrium- Where are we today?
The Thin endometrium- Where are we today?
 
Endometrial Receptivity Array- Dr Kaberi Banerjee
Endometrial Receptivity Array- Dr Kaberi BanerjeeEndometrial Receptivity Array- Dr Kaberi Banerjee
Endometrial Receptivity Array- Dr Kaberi Banerjee
 
Single Embryo Trasnfer- Dr Kaberi Banerjee
Single Embryo Trasnfer- Dr Kaberi BanerjeeSingle Embryo Trasnfer- Dr Kaberi Banerjee
Single Embryo Trasnfer- Dr Kaberi Banerjee
 
Chronic endometritis and its effect on Fertility
Chronic endometritis and its effect on FertilityChronic endometritis and its effect on Fertility
Chronic endometritis and its effect on Fertility
 
Cleavage vs Blastocyst- Dr Kaberi Banerjee
Cleavage vs Blastocyst- Dr Kaberi BanerjeeCleavage vs Blastocyst- Dr Kaberi Banerjee
Cleavage vs Blastocyst- Dr Kaberi Banerjee
 
Transforming Reproductive Medicine with AI
Transforming Reproductive Medicine with AITransforming Reproductive Medicine with AI
Transforming Reproductive Medicine with AI
 
Elective Single Embryo Transfer- An Insight
Elective Single  Embryo Transfer- An InsightElective Single  Embryo Transfer- An Insight
Elective Single Embryo Transfer- An Insight
 
CLEAVAGE OR BLASTOCYST EMBRYO TRANSFER
CLEAVAGE OR BLASTOCYST EMBRYO TRANSFERCLEAVAGE OR BLASTOCYST EMBRYO TRANSFER
CLEAVAGE OR BLASTOCYST EMBRYO TRANSFER
 
Fallopian tube blockage
Fallopian tube blockageFallopian tube blockage
Fallopian tube blockage
 
Evaluation of Quality of Life in Infertile Couples
Evaluation of Quality of Life in Infertile CouplesEvaluation of Quality of Life in Infertile Couples
Evaluation of Quality of Life in Infertile Couples
 
Management of IVF Pregnancy
Management of IVF PregnancyManagement of IVF Pregnancy
Management of IVF Pregnancy
 
Psychosocial & Ethical Dilemma Surrounding Fertility Preservation in Young Ca...
Psychosocial & Ethical Dilemma Surrounding Fertility Preservation in Young Ca...Psychosocial & Ethical Dilemma Surrounding Fertility Preservation in Young Ca...
Psychosocial & Ethical Dilemma Surrounding Fertility Preservation in Young Ca...
 
Myoma in Infertility Dilemmas in Management
Myoma in Infertility Dilemmas in ManagementMyoma in Infertility Dilemmas in Management
Myoma in Infertility Dilemmas in Management
 
Role of Hysteroscopy in Difficult Embryo Transfers
Role of Hysteroscopy in Difficult Embryo TransfersRole of Hysteroscopy in Difficult Embryo Transfers
Role of Hysteroscopy in Difficult Embryo Transfers
 
Role of Subcutaneous G-CSF Infusion in Thin Endometrium
Role of Subcutaneous G-CSF Infusion in Thin EndometriumRole of Subcutaneous G-CSF Infusion in Thin Endometrium
Role of Subcutaneous G-CSF Infusion in Thin Endometrium
 
Medically Complicated IVF Patient
Medically Complicated IVF PatientMedically Complicated IVF Patient
Medically Complicated IVF Patient
 
Dilemmas in Management of Fibroid
Dilemmas in Management of FibroidDilemmas in Management of Fibroid
Dilemmas in Management of Fibroid
 
Failed IVF Cycle
Failed IVF CycleFailed IVF Cycle
Failed IVF Cycle
 

Recently uploaded

Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
bkling
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...
chandankumarsmartiso
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
SwisschemDerma
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
70KRISHPATEL
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
The Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in IndiaThe Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in India
Swastik Ayurveda
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 

Recently uploaded (20)

Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
The Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in IndiaThe Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in India
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 

Pitfalls of PGTa

  • 2. WHAT IS PGS WHAT IS PGTA PROBLEMS WITH PGTA VARIOUS STUDIES
  • 3. The Earlier names of Genetic Tests on Embryos
  • 4. Current names of Genetic Tests on the Embryo
  • 5. PGTa claims to reduce implantation failure in IVF and reduce the risk of miscarriages. It is a very expensive test! Is it true?
  • 6.
  • 7. Some Facts of PGTa • All cells in any embryo doesn’t demonstrate aneuploidies i.e chromosomal abnormalities. There are only small number of cells which shows abnormalities. If embryo biopsy shows abnormal DNA, it is not the whole cell will be abnormal.
  • 8. Some Facts of PGTa • It is also observed that abnormal cells often self-destruct and some cells self- correct by themselves. This self-correction happens more in cells which makes baby than the cells which makes placenta (trophectoderm). For PGT-a, embryo biopsy is taken from trophectoderm. This shows that there is no benefit of doing blastocyst stage embryo biopsy as cells which are tested are of outer layer not the inner layer which forms the baby.
  • 9. The STAR Study • A total of 661 women (average age 33.7 ± 3.6 years) were randomized to PGT-A (n = 330) or morphology alone (n = 331). • PGT-A did not improve overall pregnancy outcomes in all women, as analyzed per embryo transfer or per ITT. There was a significant increase in OPR per embryo transfer with the use of PGT-A in the subgroup of women aged 35-40 years who had two or more embryos that could be biopsied, but this was not significant when analyzed by ITT.
  • 10. SHORT COMMUNICATION Open Access Preimplantation genetic screening- the required RCT that has not yet been carried out Raoul Orvieto1,2 Abstract The utilization of trophectoderm biopsy combined with comprehensive chromosome screening (CCS) tests for embryonic aneuploidy was recently suggested to improve IVF outcome, however, not without criticisms. The ongoing discussion on the unrestricted clinical adoption of preimplantation genetic screening (PGS) has called for a proper randomized controlled trial (RCT), aiming to further evaluate the cumulative live birth rates (LBRs) following Orvieto Reproductive Biology and Endocrinology (2016) 14:35 DOI 10.1186/s12958-016-0171-z • The utilization of trophectoderm biopsy combined with comprehensive chromosome screening (CCS) tests for embryonic aneuploidy was recently suggested to improve IVF outcome, however, not without criticisms. The ongoing discussion on the unrestricted clinical adoption of preimplantation genetic screening (PGS) has called for a proper randomized controlled trial (RCT), aiming to further evaluate the cumulative live birth rates (LBRs) following a single oocyte retrieval, utilizing all fresh and frozen embryos. Since this study seems not to appear for various reasons, we present herewith, the hypothetical required RCT based on the hitherto published literature. • After implementing data from the hitherto published literature on blastulation and aneuploidy rates, the rate of mosaicism and technical errors and implantation rates/LBRs of non-PGS day-3 and blastocyst and PGS blastocyst, we could clearly demonstrate the superiority of non-PGS embryo (day-3 and blastocyst) transfer over PGS blastocyst transfer, in terms of cumulative LBR (18.2–50 % vs 7.6–12.6 %, respectively). • We therefore believe that until the proper, non- hypothetical RCT on the efficacy of this procedure will appear, PGS should be offered only under study conditions, and with appropriate informed consents.
  • 11. Overall same , but can show as 50% and 100% Depends which data you want to show! Non PGS-50%? 10 8 6 4 2+2 -ve/+ve PGS-100%? 10 8 6 4 2 +ve Extra Cost Freezing Transfer Time Extra Cost PGS Personnel Laboratory WaitingTime
  • 12. Assumptions • Blastulation Rate- 47% • Aneuploidy Rate- 59% • IR-D3 21-50%, Non PGS D5 38-47%, PGS D5 39-65% • Mosaicism and Technical Errors reduce LBR SHORT COMMUNICATION Open Access Preimplantation genetic screening- the required RCT that has not yet been carried out Raoul Orvieto1,2 Abstract The utilization of trophectoderm biopsy combined with comprehensive chromosome screening (CCS) tests for embryonic aneuploidy was recently suggested to improve IVF outcome, however, not without criticisms. The ongoing discussion on the unrestricted clinical adoption of preimplantation genetic screening (PGS) has called for a proper randomized controlled trial (RCT), aiming to further evaluate the cumulative live birth rates (LBRs) following a single oocyte retrieval, utilizing all fresh and frozen embryos. Since this study seems not to appear for various reasons, we present herewith, the hypothetical required RCT based on the hitherto published literature. After implementing data from the hitherto published literature on blastulation and aneuploidy rates, the rate of mosaicism and technical errors and implantation rates/LBRs of non-PGS day-3 and blastocyst and PGS blastocyst, we could clearly demonstrate the superiority of non-PGS embryo (day-3 and blastocyst) transfer over PGS blastocyst transfer, in terms of cumulative LBR (18.2–50 % vs 7.6–12.6 %, respectively). Orvieto Reproductive Biology and Endocrinology (2016) 14:35 DOI 10.1186/s12958-016-0171-z
  • 13. For the propose of the analysis, we will assume that each group yielded 100 day-3 embryos and that all In a recent study [12] evaluating the accuracy of troph- ectoderm multiple biopsies using next-generation Fig. 1 The required hypothetical RCT
  • 14. • Presented reanalysis here of the recently published STAR study [8], which already has been affecting IVF practice worldwide, reveals significant shortcomings in the study’s statistical analyses. Those, however, do not change the principal conclusion of the STAR study that PGT-A does not favorably affect IVF outcomes by increasing pregnancy chances or reducing miscarriage risks. • The STAR study thus reveals that PGT-A does not beneficially affect IVF outcomes in confirmation of another relatively recent study in women 37 years and older by Kang et al. Like the STAR study, Kang et al. reported seemingly improved live birth rates following PGT-A but this outcome advantage, actually, reversed itself after correct intent-to-treat analysis of outcomes with reference cycle start: Pregnancy as well as live birth rates, indeed, ended up to be significantly higher in control non-PGT-A patients (49.5 vs 21.5% and 39.8 vs 19.9%). • Considering all presented evidence here, it is difficult to understand what further argument can be made for the continuous routine clinical utilization of PGT-A to improve IVF outcomes. • COMMENTARY Preimplantation genetic testing for aneuploidy (PGT-A) —finally revealed Raoul Orvieto1,2 & Norbert Gleicher3,4,5,6 Received: 10 December 2019 /Accepted: 27 January 2020 /Published online: 2 February 2020 # Springer Science+Business Media, LLC, part of Springer Nature 2020 Keywords PGT-A . PGS . Live-birth rate . Intention to treat . RCT Introduction Natural fecundity of women decreases gradually and more rapidly after age 37 years. This decrease is accompanied by aneuploidies. The procedure was, ther formed biopsying 1–2 blastomeres of d embryos, often given the acronym PGS This form of embryo testing has, sinc Journal of Assisted Reproduction and Genetics (2020) 37:669–672 https://doi.org/10.1007/s10815-020-01705-w
  • 15. 4/5/2021 Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation - Cornelisse, S - 2020 | Cochrane Library Authors' conclusions There is insu icient good‐quality evidence of a di erence in cumulative live birth rate, live birth rate a er the first embryo transfer, or miscarriage rate between IVF with and IVF without PGT‐A as currently performed. No data were available on ongoing pregnancy rates. The e ect of PGT‐A on clinical pregnancy rate is uncertain. Women need to be aware that it is uncertain whether PGT‐A with the use of genome‐wide analyses is an e ective addition to IVF, especially in view of the invasiveness and costs involved in PGT‐A. PGT‐A using FISH for the genetic analysis is probably harmful. The currently available evidence is insu icient to support PGT‐A in routine clinical practice. Plain language summary Available in English Español ‫ر‬ Français 한국어 Bahasa Malaysia https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005291.pub3/full 1/6 Cochrane Database of Systematic Reviews Review - Intervention New search Abstract Available in English Español ‫ر‬ Français 한국어 Background In in vitro fertilisation (IVF) with or without intracytoplasmic sperm injection (ICSI), selection of the most competent embryo(s) for transfer is based on morphological criteria. However, many women do not achieve a pregnancy even a er 'good quality' embryo transfer. One of the presumed causes is that such morphologically normal embryos have an abnormal number of chromosomes (aneuploidies). Preimplantation genetic testing for aneuploidies (PGT‐ Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation , Simone Cornelisse , Miriam Zagers , Elena Kostova , Kathrin Fleischer , Madelon Wely Sebastiaan Mastenbroek Authors' declarations of interest Version published: 08 September 2020 Version history https://doi.org/10.1002/14651858.CD005291.pub3
  • 16. Preimplantation genetic screening: what is the clinical efficiency? In the current practice of in vitro fertilization (IVF), preim- plantation genetic screening (PGS) is increasingly used to select embryos for transfer. This strategy is designed to maxi- mize the probability of embryo implantation by eliminating embryos with low implantation potential from the cohort. However, PGS is inherently imperfect. Errors may occur dur- ing the genetic analysis of the small amount of DNA collected. More importantly, mitotic mosaicism, whose precise inci- dence in the preimplantation embryo is not known, may lead to sampling errors due to the intentionally limited collec- tion of cells in the trophectoderm biopsy. In this manner, abnormal cells may be collected in an otherwise euploid em- bryo and vice versa. Therefore, it is inevitable that some normal embryos will be discarded, leading to an overall EI(idealized). The efficiency of the screening process can then be expressed as: Efficiency ¼ EIðscreenedÞ EIðidealizedÞ The percentage of embryos lost in the process can then be calculated as: % embryos lost ¼ 1 $ Efficiency The depiction of this analysis is most easily demonstrated in a graphic fashion. For this example, let us consider a hypo- thetical cohort of embryos from ‘‘good-prognosis’’ patients (2), under the age of 35 years, with multiple blastocysts in the 4AA or 4BB category, an unscreened implantation rate of 50%, and an ‘‘aneuploidy’’ rate of 40%. In the parlance of this calculation: EIðunscreenedÞ ¼ 0:50 INKLINGS • Errors may occur during the genetic analysis of the small amount of DNA collected. • Mitotic mosaicism may lead to sampling errors • Some normal embryos will be discarded, leading to an overall decrease in the cumulative pregnancy rate achievable by the eventual transfer of all embryos in the cohort. • Real possibility of damage to the blastocyst as result of the trophectoderm biopsy. • No studies have addressed the impact of trophectoderm biopsy in embryos with less than ideal morphologic characteristics, in older patients, or after an intervening cryopreservation procedure.
  • 17. Preimplantation genetic screening: what is the clinical efficiency? In the current practice of in vitro fertilization (IVF), preim- plantation genetic screening (PGS) is increasingly used to select embryos for transfer. This strategy is designed to maxi- mize the probability of embryo implantation by eliminating embryos with low implantation potential from the cohort. However, PGS is inherently imperfect. Errors may occur dur- ing the genetic analysis of the small amount of DNA collected. EI(idealized). The efficiency of the be expressed as: Efficiency ¼ EIðscreenedÞ EIðidealizedÞ The percentage of embryos lo calculated as: % embryos lost ¼ 1 $ Efficienc The depiction of this analysis in a graphic fashion. For this exam INKLINGS
  • 18. Clinical application of PGT‐A: is the price too high? T El‐Toukhy Guys and St. Thomas Hospital NHS Trust, London, UK Linked article: This is a mini commentary on K Neumann et al., pp. 710–718 in this issue. To view this article visit https://doi.org/10.1111/1471-0528.16089 Published Online 8 March 2020. Pre‐implantation genetic testing for aneuploidy (PGT‐A) continues to pro- voke interest, discussion and debate in the field of reproductive medicine. The two touted benefits of compre- hensive screening of pre‐implantation embryos for chromosomal aneuploidies in in vitro fertilisation (IVF) treat- ment are improvement in the live birth rate per cycle and reduction in miscarriage risk. Two recent large randomised trials employing two different techniques for PGT‐A (ESTEEM Trial – Verpoest et al. Hum Reprod 2018;33:1767–76 et al., Reprod Biomed Online 2019; 39:617–23). In this issue of our journal, the study of Neumann et al. (BJOG 2020;127:710–8) focused on the cost‐effectiveness of PGT‐A, using data from the ESTEEM trial. The study demonstrated the high cost of preventing one miscarriage through the application of PGT‐A, in both high‐cost and low‐cost healthcare settings. This result is con- sistent with the conclusion of a ‘theo- retical’ cost‐effectiveness study in a UK setting (Scriven, Reprod Biol Endocrinol cycles to achieve a live birth, it would seem more reasonable to use the limited resources for funding more standard IVF cycles to achieve more live births rather than chasing the possibility of fewer miscarriages and end up with fewer babies. Although the initial PGT‐A results involving day‐3 embryo biopsy and fluorescence in situ hybridisation were disappointing, it was expected that improvement in blastocyst cul- ture, embryo cryopreservation and molecular genetic testing technolo- gies would enable PGT‐A to achieve Economic analysis of preimplantation genetic testing for aneuploidy Pre‐implantation genetic testing for aneuploidy (PGT‐A) continues to pro- voke interest, discussion and debate in the field of reproductive medicine. The two touted benefits of compre- hensive screening of pre‐implantation embryos for chromosomal aneuploidies in in vitro fertilisation (IVF) treat- ment are improvement in the live birth rate per cycle and reduction in miscarriage risk. Two recent large randomised trials employing two different techniques for PGT‐A (ESTEEM Trial – Verpoest et al. Hum Reprod 2018;33:1767–76 and STAR Study – Munne et al. Fertil Steril 2019;112:1071–9) have shown no improvement in the live birth rate per IVF cycle started in screened cycles compared with no screening. The ESTEEM trial did not show a shorter time to pregnancy and the STAR study did not show a reduc- tion in the miscarriage rate associated et al., Reprod Biomed Online 2019; 39:617–23). In this issue of our journal, the study of Neumann et al. (BJOG 2020;127:710–8) focused on the cost‐effectiveness of PGT‐A, using data from the ESTEEM trial. The study demonstrated the high cost of preventing one miscarriage through the application of PGT‐A, in both high‐cost and low‐cost healthcare settings. This result is con- sistent with the conclusion of a ‘theo- retical’ cost‐effectiveness study in a UK setting (Scriven, Reprod Biol Endocrinol 2017;15:49). Both studies highlighted the financial burden of PGT‐A and emphasised that applying PGT‐A to all IVF cycles in women below the age of 40 years would be a very expensive approach to reduce the risk of miscarriage. Although it is important not to underestimate the emotional and cycles to ach would seem m the limited r more standard more live birt the possibility and end up wi Although th involving day‐ fluorescence were disappoi that improvem ture, embryo molecular gen gies would en its potential IVF outcome Reprod 2014;2 recent publica those improved the study of N 2020;127:710–8 reminder of th ased objective
  • 19. • Any Intervention that claims to increase the pregnancy rate in IVF must stand the test of time…till then must be clearly offered as an experimental test and at least should not financially drain the patient.